MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma

A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia

(2013) G. Yang et al.   BLOOD

Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma

(2013) Elodie Bohers et al.   GENES CHROMOSOMES & CANCER

XIII. Waldenström's macroglobulinaemia: an indolent B-cell lymphoma with distinct molecular and clinical features

(2013) Steven P. Treon   HEMATOLOGICAL ONCOLOGY

MYD88 expression and L265P mutation in diffuse large B-cell lymphoma

(2013) Jung-Woo Choi et al.   HUMAN PATHOLOGY

High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma

(2013) W Kraan et al.   LEUKEMIA

MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia

(2013) C Jiménez et al.   LEUKEMIA

Targeting pathological B cell receptor signalling in lymphoid malignancies

(2013) Ryan M. Young et al.   NATURE REVIEWS DRUG DISCOVERY

High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites

(2013) W Kraan et al.   Blood Cancer Journal

Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System Lymphomas

(2012) A. Gonzalez-Aguilar et al.   CLINICAL CANCER RESEARCH

MYD88 Somatic Mutation Is a Genetic Feature of Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

(2012) Anne Pham-Ledard et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Oncogenically active MYD88 mutations in human lymphoma

(2010) Vu N. Ngo et al.   NATURE